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Abstract
 
Apoptosis-associated speck-like protein containing a Caspase recruitment domain (ASC) be-
longs to a large family of proteins that contain a Pyrin, AIM, ASC, and death domain-like
(PAAD) domain (also known as PYRIN, DAPIN, Pyk). Recent data have suggested that ASC
functions as an adaptor protein linking various PAAD-family proteins to pathways involved in
nuclear factor (NF)-
 
 
 
B and pro-Caspase-1 activation. We present evidence here that the role
of ASC in modulating NF-
 
 
 
B activation pathways is much broader than previously suspected,
as it can either inhibit or activate NF-
 
 
 
B, depending on cellular context. While coexpression
of ASC with certain PAAD-family proteins such as Pyrin and Cryopyrin increases NF-
 
 
 
B ac-
tivity, ASC has an inhibitory influence on NF-
 
 
 
B activation by various proinflammatory stim-
uli, including tumor necrosis factor (TNF)
 
 
 
, interleukin 1
 
 
 
, and lipopolysaccharide (LPS). El-
evations in ASC protein levels or of the PAAD domain of ASC suppressed activation of I
 
 
 
B
kinases in cells exposed to pro-inflammatory stimuli. Conversely, reducing endogenous levels
of ASC using siRNA enhanced TNF- and LPS-induced degradation of the IKK substrate,
I
 
 
 
B
 
 
 
. Our findings suggest that ASC modulates diverse NF-
 
 
 
B induction pathways by acting
upon the IKK complex, implying a broad role for this and similar proteins containing PAAD
domains in regulation of inflammatory responses.
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Introduction
 
Proteins containing the death domain fold (DDF)
 
*
 
 play
pivotal roles in apoptosis and inflammatory responses. The
DDF represents a protein interaction motif consisting of a
bundle of (usually) six antiparallel 
 
 
 
-helices. This core
structure comprises four families of evolutionarily con-
served and closely related domain families, including the
death domains (DDs), death effector domains (DEDs),
caspase recruitment domains (CARDs), and Pyrin, AIM,
Apoptosis-associated speck-like protein containing a Cas-
pase recruitment domain (ASC), and death domain like
(PAAD; also known as PYRIN, DAPIN, Pyk) domains
(1–7).
Several DDF proteins are also known to participate in
activation of transcription factor nuclear factor (NF)-
 
 
 
B, a
family of dimeric transcription factors containing the Rel-
homology domain. In mammals, NF-
 
 
 
B family members
play critical roles in regulating expression of genes involved
in inflammatory and immune responses, including certain
cytokines, lymphokines, immunoglobulins, and leukocyte
adhesion proteins (for a review, see reference 8). NF-
 
 
 
Bs
exist in the cytoplasm in inactive form sequestered by in-
hibitory proteins called inhibitor of NF-
 
 
 
B (I
 
 
 
B). Protea-
some-dependent degradation of I
 
 
 
Bs is linked to their
phosphorylation by the I
 
 
 
B kinase (IKK) complex, which
consists of two related kinases, IKK
 
 
 
 and IKK
 
 
 
, and a
scaffold subunit IKK
 
 
 
 (Nemo; for a review, see reference
9). Phosphorylation of I
 
 
 
Bs triggers their poly-ubiquitina-
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Abbreviations used in this paper:
 
 ASC, apoptosis-associated speck-like
protein containing a Caspase recruitment domain; coIP, coimmunopre-
cipitation; CARD, Caspase-recruitment domain; DDF, death domain
fold; EMSA, electromobility gel-shift assays; GFP, green fluorescent pro-
tein, GST, glutathionine-S-transferase; I
 
 
 
B, inhibitor of NF-
 
 
 
B; IKK,
I
 
 
 
B kinase; NF, nuclear factor; PAAD, Pyrin, AIM, ASC, and death do-
main like; PAN, PAAD and NACHT containing protein. 
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tion and degradation, thus freeing NF-
 
 
 
B-family transcrip-
tion factors to enter the nucleus and transactivate promot-
ers of various target genes.
PAADs are found in diverse proteins implicated in
apoptosis, inflammation, and cancer, though their molecu-
lar mechanisms of action are largely unknown. The found-
ing member of the PAAD-family proteins, Pyrin, is mu-
tated in families with Familial Mediterranean Fever, a
hereditary hyperinflammatory response syndrome (10).
Mutant alleles of a gene encoding another PAAD-family
protein, Cryopyrin (PYPAF-1, NALP3) have been associ-
ated with familial cold auto-inflammatory syndrome,
Muckle-Wells syndrome, and Chronic infantile neurolog-
ical cutaneous and articular syndrome providing further
hints of a role for PAADs in control of inflammatory re-
sponses (11, 12). A role for some PAAD-containing pro-
teins in regulation of apoptosis has also been suggested
(13–16).
ASC consists of a NH
 
2
 
-terminal PAAD followed by a
COOH-terminal CARD, representing one of only two
genes in the human genome that encodes proteins combin-
ing these two protein interaction domains. ASC derives its
name, “apoptosis-associated speck-like protein containing a
CARD” from its reported ability to trigger apoptosis when
overexpressed in some tumor cell lines and from its local-
ization to punctuate cytosolic structures (specks; reference
15). ASC is also known as TMS1 (target of methylation-
induced silencing), and becomes inactive in 
 
 
 
40% of breast
cancers (16). Expression of ASC is found predominantly in
monocytes and mucosal epithelial cells (17). Recently, it
has been reported that, in transient transfection overexpres-
sion assays, coexpression of ASC with certain other PAAD-
family proteins (Cryopyrin, PYPAF-7) activates NF-
 
 
 
B.
However, the role of endogenous ASC has heretofore not
been explored. We report here that the PAAD of ASC as-
sociates with the IKK complex, modulating activation of
IKK
 
 
 
 and IKK
 
 
 
 by cytokines and LPS. Moreover, ASC
has dual properties as either an enhancer or suppressor of
NF-
 
 
 
B, depending on which pathways for NF-
 
 
 
B activa-
tion are stimulated.
 
Materials and Methods
 
Plasmids.
 
The complete open reading frame of ASC cDNA
and segments corresponding to ASC-PAAD or -CARD were
amplified by RT-PCR (Stratagene) from HL-60 cells and sub-
cloned in sense and antisense orientation into pcDNA3 vector
(Invitrogen) containing a NH
 
2
 
-terminal Myc epitope tag. Green
fluorescent protein (GFP) fusion-protein vectors were generated
by subcloning into pEGFP (CLONTECH Laboratories, Inc.).
Authenticity of all constructs was confirmed by DNA sequenc-
ing. Plasmids encoding IKK
 
 
 
, IKK
 
 
 
 (K44M), IKK
 
 
 
, IKK
 
 
 
(K44A), and IKK
 
 
 
 were gifts of Michael Karin (University of
California, San Diego, CA), while IKKi, and TBK1 were gifts
from Shizuo Akira (Osaka University, Osaka, Japan).
 
RT-PCR.
 
HEK293N Neo- or ASC-PAAD stable expressing
cells were treated with 20 ng ml
 
 
 
1
 
 TNF
 
 
 
 for 4 h, lysed in Trizol
reagent (GIBCO BRL), and total RNA was isolated according to
the instructions provided by the manufacturer. DNase I–treated
 
RNA (1 
 
 
 
g) was transcribed into single-stranded cDNA using
Superscript II (GIBCO BRL) and amplified for 30 cycles using
Amplitaq (CLONTECH Laboratories, Inc.) with either TRAF1
or GAPDH specific primers.
 
Cell Culture, Transfection, and Reporter Gene Assays.
 
HEK-
293N, HEK293T, and MCF7 cells were cultured in DMEM,
while THP-1 cells were cultured in RPMI 1640 medium, sup-
plemented with 10% heat-inactivated FBS. When indicated, cells
were treated with 10 to 20 ng ml
 
 
 
1
 
 TNF
 
 
 
 or IL-1
 
 
 
, or 600 ng
ml
 
 
 
1
 
 LPS for various times. Transfection of HEK293 cells was ac-
complished using Superfect (QIAGEN), while THP-1 (10
 
7
 
) cells
were transfected with Lipofectamine Plus (Life Technologies),
holding total DNA content constant. At 48 h after transfection,
stable THP-1 cells or 293N cells were selected in 650 or 800 
 
 
 
g
ml
 
 
 
1
 
 G418 (Calbiochem), respectively. MCF7 and THP-1 cells
were transfected with double-strand siRNAs on two consecu-
tive days using Oligofectamine (Life Technologies). siRNA1:
5
 
 
 
-UCAUCCUGAAUCUGAUCUUdTdT-3
 
 
 
, 5
 
 
 
-AAGAUC-
AGAUUCAGGAUGAdTdT-3
 
 
 
, siRNA2: 5
 
 
 
-GAUGCGGAA-
GCUCUUCAGUdTdT-3
 
 
 
, 5
 
 
 
-ACUGAAGAGCUUCCGCA-
UCdTdT-3
 
 
 
, siRNAcntr: 5
 
 
 
-CAAGUAUUUGACGACCGA-
GdTdT-3
 
 
 
, 5-CUCGGUCGUCAAAUACUUGdTdT-3
 
 
 
.
For NF-
 
 
 
B reporter gene assays, typically, 10
 
5
 
 cells cultured in
24-well plates in 5% serum were transfected with a total of 1 
 
 
 
g
plasmid DNA (normalized for total DNA), including 100 ng of
pNF-
 
 
 
B-LUC, pAP1-LUC, or p53-LUC (CLONTECH Labo-
ratories, Inc.) and 6 ng of a 
 
Renilla luciferase
 
 gene driven by a con-
stitutive TK promoter (pRL-TK; Promega). Lysates were ana-
lyzed using the Dual Luciferase kit (Promega).
 
Coimmunoprecipitations.
 
For immunoprecipitations, cells were
lysed in isotonic lysis buffer (150 or 500 mM NaCl, 20 mM Tris/
HCl [pH 7.4], 0.2% NP-40, 12.5 mM 
 
 
 
-glycerophosphate, 2
mM NaF, 200 
 
 
 
M to 1 mM Na
 
3
 
VO
 
4
 
, 1 mM PMSF, and 1
 
 
 
protease inhibitor mix [Roche]), using 2–8 
 
 
 
 10
 
7
 
 cells for en-
dogenous proteins. Clarified lysates were subjected to immuno-
precipitation using agarose-conjugated anti-c-Myc (Santa Cruz
Biotechnology, Inc.), or protein-G–conjugated anti-IKK
 
 
 
 (Santa
Cruz Biotechnology, Inc.), anti-IKK
 
 
 
 (BD Biosciences), or anti-
ASC antibodies (17). After incubation at 4
 
 
 
C for 4–12 h, im-
mune-complexes were washed three times in lysis buffer, sepa-
rated by SDS/PAGE, and analyzed by immunoblotting using
various antibodies as above in conjunction with ECL detection
system (Amersham Biosciences). Alternatively, lysates were di-
rectly analyzed by immunoblotting after normalization for total
protein content. Anti-Tubulin and anti-
 
 
 
-Actin antibodies were
purchased from Sigma-Aldrich, and anti–ICAM-1 and anti-GFP
antibodies were purchased from Santa Cruz Biotechnology, Inc.
 
Kinase Assays.
 
IKK
 
 
 
 or IKK
 
 
 
 were immunoprecipitated
from cell lysates, using 5 
 
 
 
 10
 
5
 
 cells for IKK transfectants and 10
 
6
 
cells for endogenous IKKs. Immune-complexes were washed
twice in lysis buffer (as above), once in lysis buffer containing
2 M urea followed by two washes in kinase buffer (20 mM Hepes
[pH 7.6], 50 mM NaCl, 20 mM 
 
 
 
-glycerophosphate, 1 mM
Na
 
3
 
VO
 
4
 
, 0.5 mM DTT), equilibrated for 5 min in kinase buffer,
adjusted to 10 mM MgCl
 
2
 
 and 1 mM DTT, and finally incubated
in 20 
 
 
 
l kinase buffer supplemented with 35 
 
 
 
M ATP, 5 
 
 
 
Ci
 
 
 
[
 
32
 
P] ATP and 1 
 
 
 
g glutathionine-S-transferase (GST)-I
 
 
 
B
 
 
 
(Santa Cruz Biotechnology, Inc.) at 30 C for 30 min (18).
NF- B DNA-binding Activity Assays. Electromobility gel-shift
assays (EMSA) were used to measure NF- B DNA-binding ac-
tivity, essentially as described (19). Briefly, 106 cells, either un-
treated or treated with TNF  for 20 min were lysed in buffer A
(10 mM Hepes, pH 8.0, 0.5% NP-40, 1.5 mM MgCl2, 10 mM1607 Stehlik et al.
KCl, 0.5 mM DTT, and 200 mM sucrose), washed twice in
buffer A, and pelleted nuclei were incubated in 1  packed cell
volume of buffer B (20 mM Hepes, pH 7.9, 1.5 mM MgCl2, 420
mM NaCl, 0.2 mM EDTA, and 1 mM DTT) overnight, clarified
supernatants diluted 1:1 in buffer C (20 mM Hepes, pH 7.9, 100
mM KCl, 0.2 mM EDTA, 20% glycerol, and 1 mM DTT). Pro-
tease and phosphatase inhibitors were added to all buffers. Nu-
clear extracts (2  g) were incubated with 10 fmole of a 32P-
end-labeled double-strand consensus NF- B oligonucleotide
(Promega) probe with or without 2  g of anti-p65 antibody or
control IgG (Santa Cruz Biotechnology, Inc.). For competition
assays, a 50  molar excess of unlabeled oligonucleotide was
added. DNA–protein complexes were separated by nondenatur-
ing PAGE, and analyzed by autoradiography.
Immunofluorescence Analysis. Cells were transferred to 4-well
polylysine-coated chamber slides (LabTec), fixed in 4%
paraformaldehyde, stained with 0.4  g ml 1 of the indicated an-
tibodies (Santa Cruz Biotechnology, Inc.), followed by 4  g
ml 1 FITC and TRITC labeled secondary antibodies (DakoCy-
tomation/Molecular Probes). Both secondary antibodies were
combined and used for each well in 0.1% BSA and 1% serum.
Cells were analyzed by confocal laser-scanning microscopy
(Bio-Rad Laboratories).
Results
ASC Differentially Modulates NF- B Activity, Depending
on the Stimulus. Recently, it was reported that coexpres-
sion of ASC with Cryopyrin (PYPAF-1/NALP3) or PY-
PAF-7 (PAN6) induces NF- B activity in transient trans-
fection reporter gene assays performed in HEK293T cells
(20, 21). These cells contain essentially no detectable ASC
(unpublished data), thus avoiding contributions of the en-
dogenous ASC protein. Similar to previous reports, we ob-
served 20–70-fold inductions in NF- B activity, when
ASC was coexpressed with Cryopyrin or Pyrin in
HEK293T cells, as measured by reporter gene assays in
HEK293T cells (Fig. 1 A). In contrast, neither ASC, nor
Pyrin or Cryopyrin alone induced significant NF- B activ-
ity. The ability of ASC to collaborate with other PAAD-
containing proteins in NF- B induction was selective, as
coexpression with NAC (NALP1, DEFCAP, CARD7),
PAN1 (PYPAF-2, NALP2, NBS1), or PAN2 (PYPAF-4,
NALP4) did not result in significant NF- B activity.
During studies of the effects of ASC on NF- B induc-
tion, we noticed that expression of this protein reduced
NF- B activity in HEK293N and HEK293T (Fig. 1) and
other cell lines (unpublished data) after stimulation with
cytokine TNF . For example, TNF -induced increases in
NF- B activity were reduced by approximately half
in ASC-transfected compared with control transfected
HEK293T cells (Fig. 1 B). Not only ASC, but all proteins
which contain PAAD-domains were found to have an in-
hibitory influence on TNF -mediated induction of NF-
 B activity in these reporter gene assay experiments, in-
cluding NAC, PAN1, PAN2, and to a lesser extent Pyrin,
and Cryopyrin. When ASC was coexpressed with Pyrin or
Cryopyrin (but not NAC, PAN1, or PAN2), the net levels
of NF- B activity returned to control levels seen in
TNF -stimulated cells (Fig. 1 B).
To extend these studies to other types of stimuli known to
induce NF- B activity, we performed similar reporter gene
assays, stimulating cells with the cytokine IL-1  or transfect-
ing cells with NF- B–inducing proteins such as Bcl-10
(which has been implicated in NF- B induction by B cell
and T cell antigen receptors; reference 22) and Nod-1 (a pu-
tative intracellular sensor of LPS; reference 23). In every case
examined, transient overexpression of ASC suppressed NF-
 B activity (Fig. 1, C–E). Similar results were obtained for
several cell lines, including HEK293T, HEK293N, HeLa,
Cos7, and HT1080 cells (unpublished data). The effects of
ASC on NF- B induction were specific, in as much as over-
Figure 1. Differential effects of ASC on NF- B activa-
tion. (A and B) HEK293T cells were transfected with ei-
ther 200 ng of control plasmid or 200 ng of various plas-
mids encoding PAAD-family members (ASC, NAC,
PAN1, PAN2, Pyrin, or Cryopyrin) alone (gray bars) or in
combination with 200 ng of ASC-encoding plasmid (black
bars). Transfections also included 100 ng of pNF- B and 6
ng of pRL-TK, maintaining the total DNA of transfections
at 1  g. At 36 h after transfection, cells were either left
untreated (A) or stimulated with TNF  for 8 h (B) and
analyzed for NF- B activity by reporter gene assay. Data
represent the mean   SD (n   3) and are expressed as
fold-induction relative to cells transfected with pcDNA3
control plasmid without TNF  stimulation, and are rep-
resentative of several experiments. (C) HEK293N cells,
transfected as above, were cotransfected with IL-1RI and
IL-1RAcP and induced with IL-1  for 8 h. (D and E)
Cells were transfected with plasmids encoding Bcl-10 (D)
or Nod (E) alone or in combination with ASC, and NF- B
activity was measured. (F and G) To assess specificity of
NF- B reporter gene assays in HEK293N cells, p53 tran-
scriptional activity was determined after transfection with p53-responsive luciferase reporter plasmid pRL-p53 and stimulation the next day with DNA-
damaging drug doxorubicin (DOX) (40 ng ml 1) (F), or AP-1 transcriptional activity was determined after transfection with control or TRAF2-encod-
ing plasmids with or without ASC and the AP-1–responsive plasmid pRL-AP1 (G). Transcriptional activity was measured 1 d later by reporter gene assay
(fold induction, mean   SD; n   3).1608 NF- B Regulation by ASC and PAAD Family Proteins
expression of ASC did not interfere with transcriptional acti-
vation of p53, AP-1,  -Catenin/Tcf, as measured by re-
porter gene assays (Fig. 1, F and G; and unpublished data).
Immunoblotting experiments confirmed production of all
plasmid-derived proteins, excluding a general effect of ASC
on protein synthesis or stability (see below).
ASC Inhibits NF- B Induction via Its PAAD. To map
the domain in ASC responsible for modulation of NF- B
activity, we compared the effects of full-length ASC to
truncation mutants containing only the PAAD or CARD
domains. Neither the PAAD nor the CARD of ASC in-
duced NF- B activity when expressed by transient trans-
fection in cell lines such as HEK293N (Fig. 2 A), consistent
with a previous report (24). In TNF -stimulated cells,
both full-length ASC and the PAAD of ASC profoundly
suppressed NF- B activity, while the CARD of ASC did
not (Fig. 2 B). Inhibition of TNF -induced NF- B activ-
ity by the PAAD of ASC was dose-dependent (Fig. 2 C).
NF- B DNA binding activity was also reduced by overex-
pression of the PAAD of ASC, as measured by EMSAs us-
ing a DNA probe containing NF- B binding sites (Fig. 2
D), and correlated with reduced translocation of the p65
subunit of NF- B into the nuclei of TNF -stimulated
cells, as visualized by immunofluorescence microscopy
analysis (unpublished data).
To further explore the role of the PAAD of ASC in
modulating NF- B activity, we generated stable transfec-
tants of HEK293N cell expressing the ASC-PAAD protein.
The levels of ASC-PAAD protein produced in the stable
transfectants were determined to be comparable to the lev-
Figure 2. The PAAD of ASC regulates NF- B ac-
tivity, NF- B DNA-binding activity, and expression
of endogenous NF- B target genes. (A–C) NF- B ac-
tivity as measured by reporter gene assays. Data repre-
sent fold induction (mean   SD; n   3) and are repre-
sentative of several experiments. (A) NF- B activity
data are presented for HEK293N cells transfected with
plasmids as indicated. (B) HEK293N cells were trans-
fected with plasmids as indicated and NF- B activity
was measured after TNF  stimulation for 8 h. (C)
Dose dependence of ASC-mediated inhibition of
NF- B activity, shown by transfecting increasing
amounts of ASC-PAAD plasmid into HEK293N cells
and measuring TNF -induced NF- B activity by re-
porter gene assay 1 d later. (D) NF- B DNA-binding
activity was measured by EMSA in nuclear lysates
prepared from HEK293T cells that had been tran-
siently transfected with the indicated plasmids.
NIK(KK429,430AA) served as a control inhibiting
TNF induction of NF- B DNA-binding activity. As
indicated, either IgG or anti-p65 antibodies were
added for producing “super-shifted” DNA–protein
complexes, or in lane 2 unlabeled NF- B–binding
DNA probe was included as a competitor for demon-
strating binding specificity: band-shift (BS); super-shift
(SS); free probe (FP). (E; top panel) Expression of ASC
protein was measured by immunoblotting in THP-1
cells treated for the indicated times with 600 ng ml 1
LPS. Data represent quantification of scanned bands on
blots using densitometry, normalized for Tubulin ex-
pression, and presented as a fold-increase relative to
untreated cells. (Middle panel) HEK293N Myc-ASC-
PAAD or Neo stable transfectants were assayed for
NF- B reporter gene activity at 8 h after stimulation
with TNF  (mean   SD; n   3). (Bottom panel) Ex-
pression of Neo, ASC-PAAD in transient (trans.) and
stable transfected HEK293N cells was compared with
endogenous ASC in THP-1 cells untreated ( ) or
treated ( ) for 6 h with LPS, by immunoblotting. Ex-
pression in the stable cell line was 1.5 times that of LPS
stimulated and 2.9 times that of resting THP-1 cells. (F) HEK293N-Neo and Myc-ASC-PAAD stable transfectants were transiently transfected with plas-
mids encoding GFP or GFP-antisense ASC together with a NF- B-luciferase reporter plasmid and NF- B activity was measured 8 h after TNF  stimu-
lation. Alternatively, lysates were analyzed by immunoblotting with anti-GFP and anti-Myc antibodies. Note that the shift in molecular weight of GFP
in antisense ASC-transfected cells is due to an artificial open reading frame, created by insertion of the antisense cDNA into pEGFP. (G) HEK293N cells
were transiently transfected with either Neo control or Myc-ASC-PAAD plasmids, treated with TNF  for 4 h where indicated and lysates were SDS-
PAGE/immunoblotted using anti-TRAF1, anti-TRAF2, and anti-Tubulin antibodies to measure expression of the endogenous proteins. (H) Alterna-
tively, total RNA was isolated from stably transfected HEK293N cells and analyzed by RT-PCR for TRAF1 and GAPDH. Lanes represent:
HEK293N-Neo cells (1) untreated and (2) treated for 4 h with TNF ; and HEK293N-ASC-PAAD cells (3) untreated and (4) treated for 4 h with
TNF ; (M) molecular size marker. (I) THP-1 cells that had been stably transfected with plasmids encoding GFP or GFP-ASC-PAAD were treated with
LPS as indicated and lysates were subject to SDS-PAGE/immunoblotting using anti- ICAM-1, anti-GFP, and anti- Actin antibodies.1609 Stehlik et al.
els of ASC found endogenously in some types of cells, such
as THP-1 monocytic cells in which we have observed that
LPS stimulates expression of endogenous ASC mRNA and
protein (Fig. 2 E). Clones of HEK293N stably expressing
ASC-PAAD demonstrated  80% reduced activation of a
transfected NF- B reporter gene in response to TNF 
(Fig. 2 E), consistent with expectations from transient trans-
fection experiments. Moreover, this effect on NF- B activ-
ity in ASC-PAAD expressing HEK293N cells was confirmed
to be ASC-dependent by introducing of an ASC-antisense
plasmid, in which a cDNA fragment corresponding to
ASC-PAAD was subcloned in reverse orientation down-
stream of a GFP open reading frame (Fig. 2 F). Transfection
of various amounts of this ASC-antisense plasmid induced
concentration-dependent decreases in the amount of Myc-
ASC-PAAD protein, correlating with dose-dependent res-
toration of NF- B activity after TNF  stimulation.
Next, we evaluated whether stable expression of ASC-
PAAD interfered with TNF -induced expression of an en-
dogenous NF- B target gene, TRAF1, which contains
several NF- B binding sites in its promoter (25). While
TNF  increased TRAF1 protein and mRNA, this re-
sponse was markedly blunted in ASC-PAAD–expressing
cells (Fig. 2, G and H). Analysis of control proteins
(TRAF2, Tubulin) and control mRNA (GAPDH) demon-
strated the specificity of these results.
To extend these studies yet to another cell line, THP-1
monocytic cells were stably transfected with plasmids en-
coding either GFP or GFP fused to ASC-PAAD. LPS in-
duced expression of endogenous NF- B–inducible gene,
ICAM-1 (26), in control GFP-expressing THP-1 cells,
producing a  20-fold increase in ICAM-1 protein within
10 h (Fig. 2 I). In contrast, ICAM-1 was markedly reduced
in ASC-PAAD–expressing cells. Comparable expression of
GFP-ASC-PAAD and GFP was confirmed by immuno-
blotting with anti-GFP antibody (Fig. 2 I). Taken together,
these data indicate that ASC is capable of suppressing
TNF - and LPS-induced expression of endogenous
NF- B target genes through its PAAD.
ASC-PAAD Modulates NF- B Induction at the Level of the
IKK Complex. To map where the PAAD of ASC affects
the NF- B activation pathway, NF- B activity was in-
Figure 3. ASC inhibits NF-
 B induction at the level of the
IKK complex. (A) HEK293N
cells were transfected with 200
ng of plasmids encoding various
NF- B–inducing proteins, as in-
dicated, and either 200 or 400 ng
of ASC-encoding plasmid. NF-
 B activity was measured 1 d
later by reporter gene assays as
described above, and data pre-
sented as fold-induction relative
to cells not transfected with ef-
fector plasmids (mean   SD;
n   3). The I B M (S32, 36A)
mutant served as a negative con-
trol. (B) IKK  in vitro kinase ac-
tivity toward GST-I B  in tran-
sient transfected HEK293N cells
in response to TNF . Kinase
dead IKK  (K44M) was used as
a control for blocking TNF  in-
duction of IKK activity. Shown
are phosphorylated GST-I B ,
as well as auto-phosphorylated
IKK  and phosphorylated en-
dogenous I B , which associates
with the IKK complex. (C) In
vitro kinase assays as above were
performed using HA-IKK  and
HA-IKK  (K44A). (D) HEK-
293N cells were transiently
transfected with plasmids encod-
ing effectors of the TNF 
(TRAF2) and IL-1  (TRAF6)
pathways and in vitro kinase as-
says were performed, measuring
IKK  kinase activity on GST-
I B . (E) Endogenous IKK  ki-
nase activity was measured by in vitro kinase assay in HEK293N-ASC-PAAD or -Neo stable transfectants. The IKK  kinase assay data from five experi-
ments were quantified by scanning-densitometry analysis of the autoradiograms, and are presented below the gel as a bar graph showing fold-activity
compared with uninduced HEK293N-Neo cells, normalized to IKK  expression as determined by immunoblotting (mean   SD). KA, kinase assay;
WB, Western blot.1610 NF- B Regulation by ASC and PAAD Family Proteins
duced by transient transfection of plasmids encoding various
intracellular signal-transducers that operate within cytokine
receptor pathways leading to phosphorylation of I B, a key
event required for NF- B release. Coexpression of ASC
blocked induction of NF- B activity by the adaptor pro-
teins TRAF2 and TRAF6, the TRAF-binding kinases
TBK1 and NIK, the IKK complex constituents IKK  and
IKK , and the related kinase IKKi (Fig. 3 A). In contrast,
coexpression of ASC did not suppress reporter gene activa-
tion induced by NF- B-p65. Thus, ASC blocks upstream
of NF- B, apparently at the level of the IKK complex.
To directly evaluate the effects of ASC on IKK activity,
in vitro kinase assays were performed. For initial experi-
ments, either HA-epitope tagged IKK  (Fig. 3 B) or IKK 
(Fig. 3 C) was expressed alone or in combination with
ASC or ASC-PAAD. Then HA-IKK  or HA-IKK  was
immunoprecipitated from cell lysates, and in vitro phos-
phorylation of GST-I B  substrate was measured. As neg-
ative control, kinase-dead IKKs were used. TNF  induced
 5–10-fold increases in IKK  and IKK  activity, while
ASC or ASC-PAAD expression suppressed IKK  and
IKK  activity to essentially baseline levels (Fig. 3, B and
C). This inhibitory effect of ASC and ASC-PAAD on
IKK  and IKK  activity was not attributable to a differ-
ence in the total levels of the IKK  or IKK  proteins, as
determined by immunoblot analysis, thus confirming that
ASC suppresses activation of the IKK complex. ASC also
suppressed autophosphorylation of IKK  (Fig. 3 B) and
IKK  (unpublished data), as well as phosphorylation of as-
sociated endogenous I B , in these kinase assays. Similar
results were obtained when IKK  or IKK  was activated
in cells by transient transfection of plasmids encoding intra-
cellular signaling proteins such as TRAF2 and TRAF6
(Fig. 3 D, and unpublished data).
To extend these studies involving expression of epitope-
tagged proteins by transient transfection, the activity of en-
dogenous IKK  was evaluated using HEK293N cells sta-
bly transfected with either control or Myc-ASC-PAAD
(Fig. 3 E). ASC-PAAD potently suppressed TNF -
induced activation of endogenous IKK  in these cells, as
determined by kinase assays where immunoprecipitated
IKK  was tested for ability to phosphorylate GST-I B 
substrate in vitro. Autophosphorylation of IKK  was also
suppressed in ASC-PAAD–expressing cells. These differ-
ences in IKK  activity were not due to differences in the
total levels of IKK  protein, as determined by immuno-
blotting (Fig. 3 E).
ASC Associates with IKK  and IKK . Having mapped
the site of action of ASC to the IKK complex, we per-
formed experiments to explore whether ASC associated
with these protein kinases. In the course of our studies of
ASC, we observed that expression of ASC is induced in
myeloid-lineage hematopoietic cells such as THP-1 mono-
cytic or HL-60 monomyelocytic leukemia cell lines by LPS
and TNF  (Fig. 2 E, and unpublished data). We therefore
asked whether endogenous ASC protein could be found
associated with endogenous IKK complex components af-
ter LPS- or TNF -stimulation in these cells. Co-IP exper-
iments provided evidence of association of ASC with both
IKK  and IKK  in LPS-stimulated THP-1 and TNF -
treated HL-60 cells (Fig. 4 A, and unpublished data). These
protein interactions were reciprocally demonstrable, re-
gardless of whether immune-complexes were prepared us-
ing anti-IKK  and anti-IKK  antibodies (followed by im-
munoblotting with anti-ASC antiserum) or using anti-ASC
antiserum (followed by immunoblotting with anti-IKK 
or anti-IKK  antibodies; Fig. 4 A, and unpublished data).
We also analyzed the HEK293N-ASC-PAAD stable trans-
fectants to determine whether the PAAD is sufficient for
association with the endogenous IKK complex. Again,
coimmunoprecipitation (coIP) experiments demonstrated
specific interaction of ASC-PAAD with the endogenous
IKK complex, as indicated by the association of ASC with
IKK , IKK , as well as IKK  (Fig. 4 B).
In addition, immunofluorescence microscopy was used
to examine the intracellular location of IKK  and IKK  in
HEK293-Neo and -ASC-PAAD cells (Fig. 4, C and D). In
HEK293-Neo cells, endogenous IKK  and IKK  were
diffusely distributed throughout the cytosol. In contrast,
IKK  and IKK  relocated to filament-like structures in
HEK293N-ASC-PAAD cells, colocalizing with the ASC-
PAAD proteins. Treatment of these cells with TNF  did
not affect the colocalization of ASC-PAAD with IKKs,
nor did it affect the location of IKKs in control cells lack-
ing ASC-PAAD (unpublished data). We conclude there-
fore that the PAAD of ASC associates with endogenous
IKK - and IKK -containing protein complexes, altering
their intracellular location and suppressing cytokine- and
LPS-mediated activation of these protein kinases involved
in NF- B induction.
Suppression of Endogenous ASC Expression Enhances I B 
Degradation. As IKK activity induces phosphorylation and
subsequent degradation of I B-family proteins, we evalu-
ated the effects of the PAAD of ASC on levels of endoge-
nous I B  in these stably transfected cells, before and at
various times after TNF  stimulation. Immunoblot analysis
of lysates from HEK293N-Neo cells using anti-I B  anti-
body demonstrated the appearance of a doublet band (in-
dicative of phosphorylation of I B ) within 5 min after
TNF  simulation, followed by disappearance of I B  pro-
tein. In contrast, I B  protein levels were sustained at de-
tectable levels in ASC-PAAD–expressing HEK293N cells
despite TNF  treatment. Furthermore, the I B  doublet
band indicative of phosphorylation was not observed until
much later, at 15–30 min after stimulation (Fig. 5 A), thus
demonstrating a marked delay relative to control cells.
Though the expression of the PAAD domain of ASC in
cells interfered with IKK activation (Fig. 3) and I B  deg-
radation (Fig. 5 A) in response to proinflammatory stimuli,
these results could reflect a dominant-negative effect of this
protein domain. Consequently, the full-length ASC protein
might operate as an agonist rather than antagonist of IKK
activation. To explore the role of endogenous ASC, we
used the technique of small interfering RNA (siRNA) to
reduce ASC expression in cells, assessing the impact on
TNF - and LPS-mediated degradation of endogenous1611 Stehlik et al.
I B  by immunoblotting (for a review, see reference 27).
For these experiments, either a 19 bp double-strand RNA
corresponding to ASC nucleotides 721–741, or to nucle-
otides 474–494 was introduced into either MCF7 epithelial
cells or THP-1 monocytic cells. Both siRNAs directed
against ASC mRNA substantially reduced ASC protein lev-
els in MCF7 cells and siRNA (474–494) also to a lesser ex-
tent in differentiated THP-1 cells, while a control siRNA
molecule (c) did not (Fig. 5, B and C). These experiments
revealed that an average siRNA-mediated reduction in en-
dogenous ASC protein levels of  60% was associated with
enhanced I B  degradation in cells stimulated with TNF 
or LPS averaging  23% compared with control siRNA
transfected cells. Thus, reductions of ASC were associated
with enhanced signaling by TNF  and LPS, allowing us to
conclude that endogenous ASC functions as a suppressor of
the NF- B pathway, at least in some cellular contexts.
Discussion
PAAD (PYRIN, Dapin) domains are found in multiple
genes within the human genome, including several impli-
cated in hereditary hyperinflammation syndromes, inter-
feron responses, cancer suppression, and apoptosis induc-
tion (3). Certain PAADs are capable of homotypic
interactions with themselves or other members of the
PAAD family (20, 28, 29), suggesting opportunities for cre-
ating protein interaction networks that link various signal-
ing pathways and permit fine-tuning of responses. Re-
cently, the PAAD of ASC has been reported to bind the
corresponding PAADs of Pyrin and Cryopyrin, which are
encoded by the causative genes involved in Familial Medi-
terranean Fever and Familial Cold Autoinflammatory Syn-
drome, Muckle-Wells syndrome, and Chronic infantile
neurological cutaneous and articular syndrome, respectively
(20, 28). Furthermore, ASC reportedly collaborates with
Cyropyrin and PYPAF-7 in inducing NF- B activity, at
least in transient transfection experiments in HEK293T
cells (20, 21), requiring overexpression of both ASC and
these other PAAD-family proteins. However, as shown
here, ASC does not collaborate with all PAAD-family pro-
teins in inducing NF- B activity, and its overexpression is
associated with suppression rather than enhancement of
NF- B activity in cells stimulated with proinflammatory
Figure 4. ASC associates with IKK  and IKK . (A and B) CoIP assays were performed using THP-1 cells that had been treated with LPS for 30 min.
Cleared lysates were subject to coIP using either IgG, anti-IKK , or anti-ASC antibodies and the resulting immune-complexes were analyzed by WB us-
ing various antibodies, as indicated. (B) Cleared lysates from stable HEK293N-Neo and HEK293N-ASC-PAAD cells were subjected to coIP using either
IgG, anti-IKK , anti-IKK , or anti-Myc antibodies and the resulting immune-complexes were analyzed by WB. (C and D) Immunofluorescence analy-
sis of stably transfected HEK293N-Neo and HEK293N-ASC-PAAD cells was performed, using either anti-IKK  (C) or anti-IKK  (D) polyclonal rabbit
and goat antibodies, respectively, in combination with mouse monoclonal anti-Myc epitope antibody for detection of Myc-ASC-PAAD protein. From
left to right: Localization of FITC-labeled IKK  or IKK  is shown for Neo cells and ASC-PAAD–expressing cells, followed by localization of TRITC-
labeled Myc-ASC-PAAD, and then two-color fluorescence analysis (merge).1612 NF- B Regulation by ASC and PAAD Family Proteins
cytokines (TNF , IL-1 ) or LPS. Given our observation
that the PAAD of ASC associates with and suppresses com-
ponents of the IKK complex, it is possible that Cryopyrin
interaction with ASC dislodges ASC from the IKKs, reliev-
ing endogenous suppression of these kinases, and permit-
ting NF- B activation. Alternatively, PAAD-containing
proteins such as Cryopyrin, which are thought to self-oli-
gomerize via a nucleotide-binding NACHT domain (30),
might employ ASC as an adaptor for bridging to the IKK
complex, achieving kinase activation through an induced
proximity mechanism (31). The ultimate impact of ASC
interactions with other PAAD-family proteins may there-
fore depend on their relative ratios, where ASC can func-
tion as either an inhibitor or activator of IKK, depending
on cell context and on the stimulus used to engage path-
ways leading to the IKK complex.
We propose therefore that ASC is a dual modulator of
NF- B activation, which by virtue of its association with
IKKs, acts at a point of convergence of multiple pathways
leading to NF- B induction. The ability of ASC to either
enhance or inhibit NF- B induction, depending presum-
ably on the ratio of its levels relative to other ASC-binding
proteins, is reminiscent of proteins such as c-FLIPL, which
can function as either a pro-Caspase-8 activator or inhibi-
tor, dependent on cell context (32). Similarly, some IAP-
family proteins can either enhance or inhibit NF- B in-
duction by TNF , depending apparently on whether they
induce degradation of certain associated proteins (33, 34),
but a combination of both stimulatory and inhibitory prop-
erties has not been attributed thus far to a single protein
(e.g., cIAP1 inhibits; cIAP2 enhances). Thus, ASC may
represent the first identified protein that has dual properties
as both an inhibitor and enhancer of NF- B induction.
Though other interpretations are possible, this two-sided
nature of ASC is entirely consistent with its hypothesized
role as a molecular bridge involved in assembly of multi-
protein complexes (molecular machines), in which the cor-
rect stoichiometry of components would be necessary for
activity and where either insufficiency or excess of ASC
could interfere with complex assembly.
Evidence is presented here that ASC associates with
components of the IKK complex, the kinase complex re-
sponsible for phosphorylation of the I B family proteins
that sequester NF- B in the cytosol (for a review, see ref-
erence 35). In pilot experiments, we could not demonstrate
interaction of ASC with constituents of the IKK complex
by ectopic overexpression of ASC with epitope-tagged
IKK , IKK , or IKK  individually, as determined by coIP
experiments (unpublished data). Thus, we favor the idea
that ASC associates directly or indirectly with the assem-
bled IKK complex. However, ectopic overexpression of
single components of the IKK complex might disrupt the
complex because of changes in protein stoichometry, thus
preventing ASC binding. Interestingly, Chen et al. recently
demonstrated the existence of several additional proteins
associated with endogenous IKK complexes (36). It re-
mains to be determined whether ASC associates with IKK
complexes through one of these proteins. Also, the molec-
ular events that govern physical and functional interactions
of ASC with the IKK complex remain to be clarified, in-
cluding the possible role of posttranslational modifications
of ASC or other associated proteins. Thus, it is unclear at
present how the PAAD of ASC suppresses IKK activation
in response to proinflammatory stimuli.
Recently, we determined that another PAAD-family
protein, PAN2, can also associate with IKK  and suppress
IKK  activation by TNF  (19). Interestingly, however,
PAN2 does not appear to associate with IKK  or IKK ,
suggesting the possibility of differences in interactions with
IKK complex components compared with ASC, which
could be coimmunoprecipitated with either anti-IKK  or
anti-IKK  antibodies. Similar to ASC, however, the
PAAD of PAN2 is sufficient for interactions with and sup-
pression of IKK  (19).
Figure 5. ASC regulates I B  levels. (A) Endogenous I B  expression
was analyzed by immunoblotting in stably transfected HEK293N-Neo or
ASC-PAAD cells at various times following stimulation with TNF . The
position of unphosphorylated and phosphorylated I B  proteins are indi-
cated. (B) MCF7 cells were transfected on two consecutive days with two
different double-strand ASC siRNAs (ASC nucleotides 721–741 [ 1];
and nucleotides 474–494 [ 2]) or control (c) siRNA using Oligo-
fectamine. After 24 h, cells were either left untreated ( ) or treated with
10 ng ml 1 TNF  for 10 min ( ). Cell lysates were prepared, normalized
for protein content, and analyzed by immunoblotting with antibodies
specific for ASC (top), I B  (middle), or  Actin (bottom). (C) TPA-
differentiated THP-1 cells were transfected with ASC (ASC nucleotides
474–494 [ 2]) or control (c) siRNA on two consecutive days, then stim-
ulated the following day for 30 min with LPS. Cell lysates were analyzed
by immunoblotting for ASC (top), I B  (middle), or  Actin (bottom).
(B and C) Blots were also quantified by scanning-densitometry analysis of
the autoradiograms, and are presented below the gel as a bar graph show-
ing fold expression compared with uninduced cells, normalized to  Actin
expression as determined by immunoblotting.1613 Stehlik et al.
Though we used the PAAD domain of ASC as a probe
to demonstrate the ability of this region of ASC to func-
tionally and physically interact with IKK complex compo-
nents, it should be noted that the human genome contains
at least two genes predicted to encode PAAD-only proteins
(reference 3, and unpublished data), which are analogous to
the ASC-PAAD protein employed here in our studies.
Furthermore, we have observed that these proteins func-
tion very similar to the PAAD of ASC in their effects on
IKK and NF- B induction (unpublished data). Some pox-
viruses also contain potential ORFs encoding proteins with
significant sequence similarity to cellular PAADs, such as
the rabbit myxoma virus. Thus, endogenous and viral pro-
teins consisting of only the PAAD domain may operate as
negative regulators of IKK activation, analogous to our
studies of a fragment of ASC comprising only the PAAD
domain. Just as the mechanism by which ASC suppresses
IKK activation induced by proinflammatory stimuli is pres-
ently unknown, similarly, it remains unclear how ASC en-
hances NF- B induction when coexpressed with PAAD-
family proteins such as Pyrin, (this paper), Cyropyrin (20),
and PYPAF-7 (21). ASC has been reported to recruit Py-
rin, Cryopyrin, and PYPAF-7 into cytosolic specks (20, 21,
28), suggesting a role for these intracellular bodies in the
process of NF- B induction, but the location of IKK com-
plex proteins under these circumstances has not been as-
sessed. Future studies should therefore address the conse-
quences of Pyrin, Cryopyrin, and PYPAF-7 protein
interactions with ASC with regards to association with and
regulation of the IKK complex.
Interestingly, ASC associates with uncharacterized
structures in the cytosol of cells, forming specks. The for-
mation of speck-like structures is not merely an artifact of
protein overexpression, because they can be identified by
immunohistochemical techniques in normal tissue (17),
and because certain treatments of cultured cells can induce
speck formation by endogenous ASC (15). Indeed, the en-
dogenous ASC protein was first discovered because of its
association with Triton X-100–insoluble aggregates in
HL-60 cells pretreated with retinoic acid (15). The target-
ing of ASC to these locations requires the combination of
PAAD and CARD (unpublished data), and truncation
mutants of ASC containing only the PAAD form fila-
ment-like structures in the cytosol of cells, but fail to pro-
duce the speck-like morphology for which this protein
was named. In ASC-PAAD–expressing cells, IKK compo-
nents colocalized with these filaments, which form in a
manner reminiscent of previously identified NF- B regu-
lators, such as TRADD, RIP, and Bcl-10 (37, 38). Given
recent suggestions that the ASC-binding protein Pyrin as-
sociates with cytoskeletal proteins, it is tempting to specu-
late the ASC may associate with or coordinate formation
of a specialized site on the cytoskeleton (39). The fate of
proteins recruited to these uncharacterized complexes
where ASC localizes is unknown. We have seen no evi-
dence that ASC overexpression results in degradation of
ASC-interacting proteins. Possibly speck-like structures
targeted by ASC are sites for posttranslation protein modi-
fications or simply providing a location for sequestering
certain proteins.
ASC was originally reported to induce apoptosis when
overexpressed in certain tumor lines (15, 24). However, at
the doses of ASC-encoding plasmid employed and levels of
ASC expression attained in our experiments, we did not
observe apoptosis. Based on our findings, we propose that
ASC might modulate apoptosis under some circumstances
where NF- B is important for avoiding cell death, given
that NF- B can regulate expression of apoptosis-relevant
genes such as A20, Bcl-XL, Bfl-1, cIAP2, and others (for a
review, see reference 40). In this regard, inhibition of IKKs
is known to sensitize cells to apoptosis induction by TNF-
family death ligands (41). These effects of ASC on apopto-
sis might account for the observation that this gene is com-
monly silenced in breast cancers by gene methylation (16).
Because expression of ASC is initially low but inducible
by LPS and TNF  in THP-1 monocytic cells, we speculate
that ASC may be involved in a negative feedback suppres-
sion of pathways that induce NF- B. This inducible ex-
pression in response to a variety of proinflammatory stimuli
was also recently demonstrated in neutrophils (42). In this
way, ASC could play a role in terminating inflammatory
responses, thus ensuring that only a short burst of NF- B
activity activation occurs. This scenario is consistent with
our siRNA results where reductions in ASC were corre-
lated with enhanced I B  degradation. An alternative but
not mutually exclusive possibility is that antagonism of the
TNF , IL-1 , and LPS pathways for NF- B induction by
ASC reflects a competition between alternative pathways
for access to IKK or IKK-associated proteins. In this regard,
the physiological or pathogenic stimuli that normally en-
gage ASC and other PAAD-family proteins in NF- B in-
duction are unknown, but at least 14 members of the
PAAD family have been identified that contain leucine rich
repeats (LRRs) similar to those found in the extracellular
domains of Toll-related receptors (TLRs) and in the
CARD-family proteins Nod1 and Nod2, which are
known to bind bacterial LPS or other molecules made
by microbial pathogens. Thus, while speculative, many
PAAD-family proteins may participate in a pathway that
senses intracellular bacteria. Cross talk between this path-
way and other NF- B activation pathways, such as those
triggered by TNF , IL-1 , TLRs, and antigen receptors
(TCR, BCR), may play important roles in steering innate
and acquired immune responses toward different ultimate
outcomes. Future studies, including targeted ablation of the
gene encoding ASC in mice, will reveal the overall impor-
tance of ASC in inflammation and innate immunity.
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